BioAge is a clinical-stage biotechnology company developing a pipeline of treatments to extend healthy lifespan by targeting the molecular causes of aging. The company uses its discovery platform, which combines quantitative analysis of proprietary longitudinal human samples with detailed health records tracking individuals over the lifespan, to map out the key molecular pathways that impact healthy human aging. To date, BioAge has raised $127M from Andreessen Horowitz, Kaiser Foundation Hospitals, and others. In 2021, BioAge initiated Phase 2 clinical trials of two in-licensed drugs: BGE-117, a potent inhibitor of HIF PH, is being tested for unexplained anemia of aging, and will be developed for indications related to muscle weakness; BGE-175, a PGD2 DP1 receptor inhibitor, is being tested for COVID-19, and will be developed for disorders of the aging immune system. For additional information about BioAge, visit the company’s website at www.bioagelabs.com.
Responsibilities
Requirements
BioAge offers a comprehensive compensation package, as well as generous paid time off in addition to company-observed holidays. We provide medical, dental, and vision insurance, along with a 401(k) retirement savings plan which includes matching employer contributions. We also pride ourselves in giving employees many opportunities for career development including a generous annual budget for continued learning, a direct and open-door environment, and a dedication to training and skill development.
BioAge is an equal opportunity employer. In accordance with anti-discrimination law, it is the purpose of this policy to effectuate these principles and mandates. BioAge prohibits discrimination and harassment of any type and affords equal employment opportunities to employees and applicants without regard to race, color, religion, sex, national origin, disability status, protected veteran status, or any other characteristic protected by law. BioAge conforms to the spirit as well as to the letter of all applicable laws and regulations.